Industry Strength Score
24/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
MEDICURE INC (MPH.CA) Stock Price & Overview
TSX-V:MPH • CA58469E4085
Current stock price
0.95 CAD
+0.05 (+5.56%)
Last:
The current stock price of MPH.CA is 0.95 CAD. Today MPH.CA is up by 5.56%. In the past month the price decreased by -15.18%. In the past year, price increased by 4.4%.
MPH.CA Key Statistics
52-Week Range0.63 - 1.43
Current MPH.CA stock price positioned within its 52-week range.
1-Month Range0.85 - 1.35
Current MPH.CA stock price positioned within its 1-month range.
- Market Cap
- 9.918M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.33
- Dividend Yield
- N/A
MPH.CA Stock Performance
Today
+5.56%
1 Week
-15.18%
1 Month
-15.18%
3 Months
-16.67%
Longer-term
6 Months -17.39%
1 Year +4.40%
2 Years -11.22%
3 Years -24.60%
5 Years -40.25%
10 Years -83.16%
MPH.CA Stock Chart
MPH.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MPH.CA. When comparing the yearly performance of all stocks, MPH.CA is a bad performer in the overall market: 82.93% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
MPH.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA. The financial health of MPH.CA is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MPH.CA Earnings
On April 22, 2026 MPH.CA reported an EPS of -0.13 and a revenue of 8.33M.
Next Earnings DateMay 19, 2026
Last Earnings DateApr 22, 2026
PeriodQ3 / 2025
EPS Reported-CA$0.13
Revenue Reported8.33M
EPS Surprise %
Revenue Surprise %
MPH.CA Forecast & Estimates
Analysts
Analysts40
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
MPH.CA Financial Highlights
Over the last trailing twelve months MPH.CA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -68.69% compared to the year before.
Income Statements
Revenue(TTM)26.21M
Net Income(TTM)-3.43M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.83% | ||
| ROE | -19.81% | ||
| Debt/Equity | 0.03 |
Chartmill High Growth Momentum
EPS Q2Q%-279.68%
Sales Q2Q%56.6%
EPS 1Y (TTM)-68.69%
Revenue 1Y (TTM)24.3%
MPH.CA Ownership
Ownership
Inst Owners23.1%
Shares10.44M
Float7.63M
Ins Owners26.42%
Short Float %N/A
Short RatioN/A
MPH.CA Industry Overview
MPH.CA operates in the Biotechnology sub-industry within the Health Care sector. This group contains 18 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
11/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
71%
Outperformed 71% of sub-industries
3 Month Rank
36%
Outperformed 36% of sub-industries
6 Month Rank
29%
Outperformed 29% of sub-industries
Industry Fundamentals & Breadth
- Members
- 18
- New Highs
- 0%
- New Lows
- 11.1%
- Average ROE
- 3.7%
- Average Profit Margin
- 3.1%
- Average Operating Margin
- 1.6%
- Average P/E
- 63.0
- Average Fwd P/E
- 9.2
- Average Debt/Equity
- 0.1
MPH.CA Competitors/Peers
The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 596.444M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 404.92M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 144.358M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.11 | 52.478M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 50.886M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.73M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 3.54 | 35.885M | ||
| RVX | RESVERLOGIX CORP | N/A | 33.198M | ||
| HEM | HEMOSTEMIX INC | N/A | 13.845M | ||
| CSCI | COSCIENS BIOPHARMA INC | N/A | 8.268M | ||
| KNE | KANE BIOTECH INC | N/A | 6.365M | ||
| QPT | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the TSX Venture Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About MPH.CA
Company Profile
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
Company Info
IPO: 1999-03-30
MEDICURE INC
1250 Waverley Street
Winnipeg MANITOBA R3T 6C6 CA
CEO: Albert D. Friesen
Employees: 38
Phone: 12044877412
MEDICURE INC / MPH.CA FAQ
Can you describe the business of MEDICURE INC?
Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.
What is the current price of MPH stock?
The current stock price of MPH.CA is 0.95 CAD. The price increased by 5.56% in the last trading session.
Does MEDICURE INC pay dividends?
MPH.CA does not pay a dividend.
How is the ChartMill rating for MEDICURE INC?
MPH.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does MEDICURE INC have?
MEDICURE INC (MPH.CA) currently has 38 employees.